Fidelity Investments’s TransCode Therapeutics RNAZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$18 Sell
11
-695
-98% -$2.89K ﹤0.01% 5690
2026
Q2
$4.38K Buy
+706
New +$4.8K ﹤0.01% 5043
2025
Q3
– Sell
-3
Closed -$23 – 5553
2025
Q2
$23 Buy
3
+2
+200% +$19 ﹤0.01% 5260
2025
Q1
$12 Buy
+1
New +$128 ﹤0.01% 5243
2024
Q4
– Hold
0
– -$100 – 5774
2024
Q3
– Hold
0
– – – 5096

Other funds holding RNAZ

Fidelity Investments's RNAZ Position: Q3 2026 in Review

Fidelity Investments reduced its TransCode Therapeutics (RNAZ) stake by 98% in Q3 2026, selling an estimated $2.89K and leaving 11 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #5690.

Fidelity Investments first reported a position in RNAZ in Q1 2025 and has held it in 4 quarters since. The position peaked at $4.38K in Q2 2026. 12 funds tracked by Wall St. Rank hold RNAZ as of Q3 2026.

  • Fidelity Investments held 11 shares of TransCode Therapeutics worth $18 as of Q3 2026.
  • Fidelity Investments sold 695 TransCode Therapeutics shares in Q3 2026, an estimated $2.89K.
  • TransCode Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #5690 holding.
  • Fidelity Investments first reported a position in TransCode Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Fidelity Investments's TransCode Therapeutics position peaked at $4.38K in Q2 2026.
  • 12 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.